October 23–26, 2025 — The 30th Congress of Chinese Pediatric Society of the Chinese Medical Association was successfully held in Xiamen, Fujian. As one of the most prestigious and influential academic events in China’s pediatric field, the conference gathered leading pediatric experts and scholars from across China and abroad to exchange insights on the latest advances in pediatric medicine. The latest clinical findings of Puzolcabtagene Autoleucel Injection--a CAR-T cell therapy candidate independently developed by Chongqing Precision Biotech for the treatment of leukemia in children and adolescents—were officially released at the congress.

During the opening ceremony and keynote session, Professor Wang Tianyou of Beijing Children’s Hospital, Capital Medical University, delivered a speech titled “Current Status of Diagnosis and Treatment of Pediatric Hematologic Malignancies in China”. In his talk, he highlighted key clinical data from the Puzolcabtagene Autoleucel study. At the oncology sub-forum, two symposiums (Chaired by Prof. Wang Tianyou and Prof. Jiang Hua; Speakers: Prof. Yang Wenyu and Prof. Li Benshang) provided a comprehensive overview of the pivotal clinical data of Puzolcabtagene Autoleucel Injection and conducted in-depth discussions on the therapeutic potential and unique advantages of CAR-T cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).  

During the conference, Xia Junli, Director of Marketing at Chongqing Precision Biotech, led the core team in in-depth discussions with pediatric hematology experts from several leading hospitals across the country, focusing on key product information and future collaboration opportunities.